Director dealings: Puretech Health director raises stake
22nd Jul 2021 15:35
(Sharecast News) - Puretech Health revealed on Thursday that director Bharatt Chowrira had acquired 25,000 ordinary shares in the FTSE 250-listed biotechnology company.
Read morePuretech Health narrows FY operating losses after cutting expenses
15th Apr 2021 07:52
(Sharecast News) - Biotechnology company Puretech Health said on Thursday that it had narrowed operating losses in 2020 on the back of a reduction in general and administrative expenses and a modest increase in full-year revenues.
Read morePureTech sells down Karuna stake as Vor closes IPO
10th Feb 2021 09:22
(Sharecast News) - Clinical-stage biotherapeutics commercialisation company PureTech Health announced on Wednesday that its founded entity Vor Biopharma has closed its initial public offering at a price of $18 per share.
Read morePureTech appoints George Farmer as new finance chief
5th Jan 2021 08:26
(Sharecast News) - Clinical-stage biotherapeutics company PureTech Health announced on Tuesday that George Farmer has been appointed chief financial officer.
Read morePureTech Health eyes Nasdaq listing for ADS
28th Oct 2020 08:01
(Sharecast News) - Clinical-stage biotherapeutics company PureTech Health has filed a public registration statement to the US Securities and Exchange Commission as it looks to list its American depository shares on the Nasdaq.
Read moreLiberum raises target price on 'underappreciated' PureTech Health
29th Jul 2020 15:00
(Sharecast News) - Analysts at Liberum raised their target price on biotechnology company PureTech Health from 450.0p to 490.0p on Wednesday, stating the firm had made some "underappreciated" progress.
Read moreWednesday broker round-up
29th Jul 2020 13:29
(Sharecast News) - Sanne: RBC Capital Markets reiterates sector performer with a target price of 600.0p.
Read moreSunday share tips: PureTech, Driver Group
12th Jul 2020 16:51
(Sharecast News) - The Sunday Times's Sabah Meddings told readers of her 'Inside the City' column to 'buy' shares of PureTech, citing the the drug maker's ingenious 'portfolio' approach and ample pipeline of treatments in various phases of development.
Read morePeel Hunt says Vor Biopharma cash call validates Puretech Health's model
8th Jul 2020 15:13
(Sharecast News) - Analysts at Peel Hunt reiterated their 'Conviction Buy' recommendation for shares of PureTech Health following a $110.0m funding round for its founded entity Vor Biopharma, arguing that the transaction validated its business model.
Read morePureTech's Akili gets CE-mark for 'EndeavourRx'
23rd Jun 2020 07:29
(Sharecast News) - Biotherapeutics company PureTech Health said its founded entity Akili had received a CE-mark for 'EndeavorRx treatment for attention deficit hyperactivity disorder (ADHD).
Read morePureTech gets FDA clearance for video game ADHD treatment
16th Jun 2020 07:29
(Sharecast News) - Clinical-stage biotherapeutics company PureTech Health announced on Tuesday that its subsidiary Akili has been granted US Food and Drug Administration (FDA) clearance for 'EndeavorRx', or AKL-T01, as a prescription treatment for children with attention deficit hyperactivity disorder (ADHD).
Read morePureTech Health sees 'positive' topline data from Phase 1 on IBD candidate
9th Jun 2020 08:40
(Sharecast News) - Clinical-stage biotherapeutics company PureTech Health reported some "positive" topline data from two Phase 1 studies into VE202, its orally-administered inflammatory bowel disease treatment candidate.
Read morePureTech firm Gelesis gets Europe approval for 'Plenity'
2nd Jun 2020 07:37
(Sharecast News) - Clinical stage biotherapeutics company PureTech Health announced on Tuesday that its founded company Gelesis has received approval to market 'Plenity', a novel weight-loss treatment, in Europe.
Read morePureTech to advance LYT-100 as potential Covid treatment
28th May 2020 07:57
(Sharecast News) - PureTech Health announced plans on Thursday to advance its wholly-owned clinical-stage product candidate 'LYT-100', or deupirfenidone, as a potential treatment for serious respiratory complications, including inflammation and fibrosis, that persist following the resolution of Covid-19 infection.
Read morePureTech Health lowers stake in founded entity
26th May 2020 08:51
(Sharecast News) - Clinical stage biotechnology company PureTech Health said on Tuesday that it had received $45m from the sale of 555,500 shares of its founded entity Karuna Therapeutics.
Read more